Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P26640
UPID:
SYVC_HUMAN
Alternative names:
Protein G7a; Valyl-tRNA synthetase
Alternative UPACC:
P26640; B0V1N1; B4DZ61; Q5JQ90; Q96E77; Q9UQM2
Background:
Valine--tRNA ligase, also known as Protein G7a and Valyl-tRNA synthetase, plays a crucial role in protein synthesis by catalyzing the attachment of valine to tRNA(Val). This enzyme is essential for the translation of genetic information into functional proteins.
Therapeutic significance:
The protein is linked to a neurodevelopmental disorder characterized by severe developmental delay, intellectual disability, and cortical atrophy. Understanding the role of Valine--tRNA ligase could open doors to potential therapeutic strategies for this debilitating condition.